Central Ohio Breast and Endocrine Surgery

Gahanna, Ohio 43230

8 studies enrolling now · 57 studies all time

What they study most

Acral Lentiginous Melanoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anatomic Stage I Breast Cancer AJCC v8

Studies at this site

• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer — Recruiting now
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study — Recruiting now
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) — Recruiting now
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — Recruiting now
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors — Recruiting now
• Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects — Recruiting now
• mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma — Recruiting now
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease — Recruiting now
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma — Recruiting now
• Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials — Recruiting now
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial — Recruiting now
• Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) — Recruiting now
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma — Recruiting now
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer — Recruiting now
• Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors — Recruiting now
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases — Recruiting now
• Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer — Running, not enrolling
• Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia — Running, not enrolling
• EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients — Running, not enrolling
• NCI COVID-19 in Cancer Patients, NCCAPS Study — Running, not enrolling
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — Running, not enrolling
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma — Running, not enrolling
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents — Running, not enrolling
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer — Running, not enrolling
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia — Running, not enrolling
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations — Running, not enrolling
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study — Running, not enrolling
• Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors — Running, not enrolling
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Running, not enrolling
• Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread — Running, not enrolling
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer — Running, not enrolling
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone — Running, not enrolling
• Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer — Running, not enrolling
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial — Running, not enrolling
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer — Running, not enrolling
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer — Stopped early
• S0820, Adenoma and Second Primary Prevention Trial — Running, not enrolling
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Running, not enrolling
• Testing Ramipril to Prevent Memory Loss in People With Glioblastoma — Completed
• A Study of miRNA 371 in Patients With Germ Cell Tumors — Running, not enrolling
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer — Running, not enrolling
• Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial — Running, not enrolling
• Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors — Running, not enrolling
• Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers — Running, not enrolling
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers — Completed
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Running, not enrolling
• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration — Running, not enrolling
• Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer — Completed
• Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial — Completed
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Completed